BNC210

BNC210

Clinical data
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name L-Isoleucyl-L-tryptophan
PubChem CID	7019084
ChemSpider	5382052
Chemical and physical data
Formula	C17H23N3O3
Molar mass	317.39 g·mol−1
3D model (Jmol)	Interactive image
SMILES CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N
InChI InChI=1S/C17H23N3O3/c1-3-10(2)15(18)16(21)20-14(17(22)23)8-11-9-19-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,14-,15-/m0/s1 Key:BVRPESWOSNFUCJ-LKTVYLICSA-N

BNC210 (also known as IW-4123 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α₇-nicotinic acetylcholine receptor, by Bionomics Limited. It demonstrates clinically significant anxiety reduction in both animal models and in Phase I trials.

It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.

Phase I trials have shown no serious side effects.

Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States, but in November 2014, was released back to Bionomics in a mutual agreement. Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.

As of April 2015, BNC210 is in phase II clinical trials.